Health & Fitness
Health and Fitness
Health and Fitness
Thu, October 28, 2010Wed, October 27, 2010Tue, October 26, 2010Mon, October 25, 2010Sun, October 24, 2010Sat, October 23, 2010Fri, October 22, 2010Thu, October 21, 2010Wed, October 20, 2010Tue, October 19, 2010Mon, October 18, 2010Sun, October 17, 2010Sat, October 16, 2010Fri, October 15, 2010Thu, October 14, 2010Wed, October 13, 2010Tue, October 12, 2010Mon, October 11, 2010Sun, October 10, 2010Sat, October 9, 2010Fri, October 8, 2010Thu, October 7, 2010Compugen Ltd. to Review Third Quarter 2010 Financial Results on Tuesday, October 26, 2010
Published in Health and Fitness on Tuesday, October 19th 2010 at 4:11 GMT by Market Wire
TEL AVIV, Israel--([ BUSINESS WIRE ])--Compugen Ltd. [ (NASDAQ: CGEN) ] today announced that the Company plans to host a live conference call and webcast at 10:00 AM EDT on Tuesday, October 26, 2010 to review third quarter 2010 results. The quarterly results will be released prior to the conference call.
To access the conference call, please dial 1-866-860-9642 from the US or 972-3-918-0609 internationally. The call will also be available via live webcast through Compugena™s website, located at the following [ link ].
A replay of the conference call will be available approximately two hours after the completion of the live conference call. To access the replay, please dial 1-888-782-4291 from the US or 972-3-925-5901 internationally. The replay will be available until 12 noon EDT on October 29, 2010.
About Compugen
Compugen is a leading drug and diagnostic product candidate discovery company. Unlike traditional high throughput trial and error experimental based discovery, Compugena™s discovery efforts are based onin silico (by computer) prediction and selection utilizing a growing number of field focused proprietary discovery platforms accurately modeling biological processes at the molecular level. Compugena™s growing number of collaborations with major pharmaceutical and diagnostic companies cover both (i) the licensing of product candidates discovered by Compugen during the validation of its discovery platforms and in its internal research, and (ii) adiscovery on demanda agreements where existing or new Compugen discovery platforms are utilized to predict and select product candidates as required by a partner. In 2002, Compugen established an affiliate, Evogene Ltd.([ www.evogene.com ])(TASE: EVGN), to utilize certain of the Companya™sin silicopredictive discovery capabilities in agricultural biotechnology. For additional information, please visit Compugen's corporate website at[ www.cgen.com ].
This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as amay,a aexpects,a aanticipates,a abelieves,a and aintends,a and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; and the ability to implement technological improvements. These and other factors are identified and more fully explained under the heading "Risk Factors" in Compugen's annual reports filed with the Securities and Exchange Commission.
